Survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer who were treated with platin-based adjuvant chemotherapy.

IF 1.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Turkish Journal of Medical Sciences Pub Date : 2025-03-06 eCollection Date: 2025-01-01 DOI:10.55730/1300-0144.5980

Mehmet Ünsal, Meltem Yücesoy, Okan Oktar, Yeşim Uçar, Gülşah Tiryaki Güner, Okan Aytekin, A Alp Tokalioğlu, Hande Esra Koca Yildirim, Fatih Kiliç, Burak Ersak, Caner Çakir, Dilek Yüksel, Çiğdem Kiliç, Sevgi Koç, Günsu Kimyon Cömert, Özlem Moraloğlu Tekin, Yaprak Engin Üstün, Taner Turan

{"title":"Survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer who were treated with platin-based adjuvant chemotherapy.","authors":"Mehmet Ünsal, Meltem Yücesoy, Okan Oktar, Yeşim Uçar, Gülşah Tiryaki Güner, Okan Aytekin, A Alp Tokalioğlu, Hande Esra Koca Yildirim, Fatih Kiliç, Burak Ersak, Caner Çakir, Dilek Yüksel, Çiğdem Kiliç, Sevgi Koç, Günsu Kimyon Cömert, Özlem Moraloğlu Tekin, Yaprak Engin Üstün, Taner Turan","doi":"10.55730/1300-0144.5980","DOIUrl":null,"url":null,"abstract":"Background/aim: Epithelial ovarian cancer is the second most prevalent type of gynecological cancer. We aimed to investigate prognostic factors related to survival in patient with 2014 FIGO stage IIIC high-grade serous ovarian cancer (HGSOC).Materials and methods: Two hundred fifty eight patients were evaluated retrospectively. The absence of a visible tumor was determined as maximum cytoreduction, and a residual tumor size of 1 cm or less was determined as optimal cytoreduction. Patients who underwent cytoreduction followed by a combination of platinum and taxane adjuvant chemotherapy were included. Exclusion criteria for the study were patients taking neoadjuvant chemotherapy and those with suboptimal surgery.Results: Optimal cytoreduction was performed in 107 and maximal cytoreduction was performed in 151 patients. The five-year PFS rate was 27% and the five-year DSS rate was 76%. While high ascites volume and optimal cytoreduction were identified as independent prognostic factors for disease failure, only optimal cytoreduction was an independent prognostic factor for survival.Conclusion: The maximal cytoreduction is improves PFS and DSS in patients with 2014 FIGO stage IIIC HGSOC as our study results. Therefore, maximum surgical effort and radical cytoreductive procedures should be performed.","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 2","pages":"368-376"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058003/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55730/1300-0144.5980","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Epithelial ovarian cancer is the second most prevalent type of gynecological cancer. We aimed to investigate prognostic factors related to survival in patient with 2014 FIGO stage IIIC high-grade serous ovarian cancer (HGSOC).

Materials and methods: Two hundred fifty eight patients were evaluated retrospectively. The absence of a visible tumor was determined as maximum cytoreduction, and a residual tumor size of 1 cm or less was determined as optimal cytoreduction. Patients who underwent cytoreduction followed by a combination of platinum and taxane adjuvant chemotherapy were included. Exclusion criteria for the study were patients taking neoadjuvant chemotherapy and those with suboptimal surgery.

Results: Optimal cytoreduction was performed in 107 and maximal cytoreduction was performed in 151 patients. The five-year PFS rate was 27% and the five-year DSS rate was 76%. While high ascites volume and optimal cytoreduction were identified as independent prognostic factors for disease failure, only optimal cytoreduction was an independent prognostic factor for survival.

Conclusion: The maximal cytoreduction is improves PFS and DSS in patients with 2014 FIGO stage IIIC HGSOC as our study results. Therefore, maximum surgical effort and radical cytoreductive procedures should be performed.

查看原文本刊更多论文

2014年FIGO IIIC期高级别浆液性卵巢癌患者接受以铂为基础的辅助化疗的生存率

背景/目的：上皮性卵巢癌是第二常见的妇科癌症。我们的目的是研究2014年FIGO IIIC期高级别浆液性卵巢癌（HGSOC）患者生存相关的预后因素。材料与方法：对258例患者进行回顾性分析。没有可见肿瘤被确定为最大的细胞减少，残余肿瘤大小为1厘米或更小被确定为最佳的细胞减少。患者接受细胞减少后，铂和紫杉烷辅助化疗的组合包括在内。该研究的排除标准是接受新辅助化疗的患者和手术不理想的患者。结果：最佳细胞减少107例，最大细胞减少151例。5年PFS为27%，5年DSS为76%。虽然高腹水容量和最佳细胞减量被确定为疾病失败的独立预后因素，但只有最佳细胞减量是生存的独立预后因素。结论：2014 FIGO IIIC期HGSOC患者的最大细胞减量改善了PFS和DSS，是我们的研究结果。因此，应该进行最大的手术努力和彻底的细胞减少手术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Journal of Medical Sciences 医学-医学：内科

CiteScore

4.60

自引率

4.30%

发文量

143

审稿时长

3-8 weeks

期刊介绍： Turkish Journal of Medical sciences is a peer-reviewed comprehensive resource that provides critical up-to-date information on the broad spectrum of general medical sciences. The Journal intended to publish original medical scientific papers regarding the priority based on the prominence, significance, and timeliness of the findings. However since the audience of the Journal is not limited to any subspeciality in a wide variety of medical disciplines, the papers focusing on the technical details of a given medical subspeciality may not be evaluated for publication.